

Reference List: CellGro® / CellGenix™ Products

CellGro® DC Medium and Cytokines

M. Eyrich et al. (2014)

Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. Cytotherapy 16:946-964

P. Lazarova, G. Kvalheim et al. (2011)

Is anticancer vaccine possible: Experimental application of produced mRNA transfected dendritic cells derived from enriched CD34* blood progenitor cells. Immunology and Microbiology: Immuno-deficiency, ed. K. Metodiev, chapter 3

A. ten Brinke et al. (2010)

Monophosphoryl lipid A plus IFN-gamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential. Cancer Immunol. Immunother. 59(8):1185-95

P.J. Hanley et al. (2009)

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 114:1958-67

A.M. Dohnal et al. (2009)

Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. J. Cell. Mol. Med. 13:125-35

I. Möller et al. (2008)

Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application. J Immunother. 31(5):506-19

L.H. Butterfield et al. (2008)

[Clinical Study] Development of a Potency Assay for Human Dendritic Cells: IL-12 p70 Production. J. Immunotherapy, 31(1): 89-100

E. Ovali et al. (2007)

Active Immunotherapy for Cancer Patients Using Tumor Lysate Pulsed Dendritic Cell Vaccine: a Safety Study. J. Exp. Clin. Cancer Res., 26(2): 209-214

A. Curti et al. (2007)

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br. J. Haemat., 139(3): 415-24

W.J. Lesterhuis, I.J.M. de Vries et al. (2006)

Vaccination of colorectal cancer patients with CEA-loaded dendritic cells : antigen-specific T-cell responses in DTH skin tests. Annals Oncology, 17:974-80

M. Rapp et al. (2006)

Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J. Neurosurg., 105: 41-50

J.A. Kyte, G. Kvalheim et al. (2005)

Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther., 12(6):579-91.

Manufacturer

CellGenix GmbH
Am Flughafen 16 | 79108 Freiburg | Germany
Tel. +49 761 88889-0 | Fax +49 761 88889-830
www.cellgenix.com | info@cellgenix.com

CellGro® is a registered trademark
of CellGenix in several global markets.
In North America and a few other countries
CellGro® reagents are marketed under CellGenix™.

Reference List: CellGro® / CellGenix™ Products

S. Jarnjak-Jankovic et al. (2005)

Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumor mRNA as potential cancer vaccines against leukaemia. *BMC Cancer*, 5:20

W. Lu et al. (2004)

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. *Nature Medicine* 10(12):1359-65

Motta M.R., Castellani S. et al. (2003)

Generation of dendritic cells from CD14⁺ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. *British Journal of Hematology*, 121, 240-250

CellGro® DC Cytokines

M. Hansen et al. (2013)

Comparison of clinical grade type1 polarized and standard matured dendritic cells for cancer immunotherapy. *Vaccine* 31:639-646

T. Berger et al. (2009)

Immature and maturation-resistant human dendritic cells generated from bone marrow require two stimulations to induce T cell anergy in vitro. *PLoS One* 4:e6645

A.-K. Thomas-Kaskel et al. (2007)

Allogeneic HLA-Matched Donor Dendritic Cells Loaded with Patient Leukemic Blasts Preferentially Induce CD4-Positive Leukemia-Reactive Donor Lymphocytes. *Acta Haematol.*, 117: 226-235

M. Condomines et al. (2006)

Functional Regulatory T Cells are Collected in Stem Cell Autografts by Mobilisation with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor. *J. Immunology*, 177(10): 6631-6639

M. Erdmann et al. (2006)

Effective Clinical-scale Production of Dendritic Cell Vaccines by Monocyte Elutriation Directly in Medium, Subsequent Culture in Bags and Final Antigen Loading Using Peptides or RNA Transfection. *J. Immunother.*, 30(6): 663-674

H. Barth et al. (2005)

Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. *Blood*, 105(9): 3605-3614

Szmania S., Yi Q., Cottler-Fox M. et al (2005)

Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation. *Cyotherapy* 7(4): 374-384

D.H. Chang et al. (2005)

Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. *J. Exp. Med.*, 201(9): 1503-1517

I.M. Svane et al. (2004)

Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. *Cancer Immunol Immunother*, 53: 663-641

Sorg R.V., Özcan Z., Brefort T. et al. (2003)

Clinical-Scale Generation of Dendritic Cells in a Closed System. *J Immunotherapy*, 26(4):374-383

Manufacturer

CellGenix GmbH
Am Flughafen 16 | 79108 Freiburg | Germany
Tel. +49 761 88889-0 | Fax +49 761 88889-830
www.cellgenix.com | info@cellgenix.com

CellGro® is a registered trademark
of CellGenix in several global markets.
In North America and a few other countries
CellGro® reagents are marketed under CellGenix™.



Reference List: CellGro® / CellGenix™ Products

CellGro® DC Medium

S.T.H.M Kolanowski et al. (2014)

Comparison of media and serum supplementation for generation of monophosphoryl lipid A / interferon- γ -matured type I dendritic cells for immunotherapy. Cytotherapy 16:826-834

CL.L. Chiang et al. (2011)

Optimizing parameters for clinical scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor lysate. J. Transl. Med. 9:198

J. Fucikova et al (2011)

Poly I: C-activated dendritic cells that were generated in CellGro® for use in cancer immunotherapy. J. Transl. Med. 9:223

Kalinski, P. et al. (2010)

Generation of stable Th1/CTL-, Th2-, and Th17-inducing human dendritic cells. Methods Mol Biol 595:117-33

H.S. Garritsen et al. (2010)

Efficient generation of clinical-grade genetically modified dendritic cells for presentation of multiple tumor-associated proteins. Transfusion 50(4):831-42

JJ Lee et al. (2008)

Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol. 84(1):319-25

H. Xiong et al. (2007)

Enhanced interferon- γ secretion and antitumor activity of T-lymphocytes activated by dendritic cells loaded with glycoengineered myeloma antigens. Chin. Med. J., 120(19): 1678-1684

A. Leen et al. (2007)

Contact-activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T Cells. J. Immunother., 30(1): 96-107

C. Napoletano et al. (2007)

A Comparative Analysis of Serum and Serum-free Media for Generation of Clinical Grade DCs. J. Immunother., 30(5): 567-576

I. Houtenbos et al. (2007)

Leukemia-Specific T-Cell Reactivity Induced by Leukemic Dendritic Cells Is Augmented by 4-1BB Targeting. Clin. Can. Res. 13(1): 307-15

A. Gaikwad et al. (2007)

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in *JAK2V617F* allele. Exp. Hematology, 35(4): 587-94

D.E.H. Heinemann, J.H. Peters (2005)

Follicular dendritic-like cells derived from human monocytes. BMC Immunology, 6:23

Manufacturer

CellGenix GmbH
Am Flughafen 16 | 79108 Freiburg | Germany
Tel. +49 761 88889-0 | Fax +49 761 88889-830
www.cellgenix.com | info@cellgenix.com

CellGro® is a registered trademark
of CellGenix in several global markets.
In North America and a few other countries
CellGro® reagents are marketed under CellGenix™.



Reference List: CellGro® / CellGenix™ Products

CellGro® DC Medium and T cell cytokines

M. Wölfel, P. Greenberg et al. (2014)

Antigen-specific activation and cytokine-facilitated expansion of naive CD8+ T cells. Nature Protocols Vol. 9, 950–966

CellGro® DC Medium for T cells

A.M. Rasmussen et al. (2010)

Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. J Immunol Methods. 355(1-2):52-60

CellGro® SCGM and HPC Cytokines

D.J. Steiner et al. (2009)

Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo- expanded CD34-selected umbilical cord blood cells. Stem Cells 27:1932-40

H. El-Daly et al. (2005)

Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood, 105: 1742-49

Querol S. (2003)

Ex vivo production of cord blood CD34+ derived myeloid precursors after serum-free static culture. Meth Mol Biol. 215:351-62

CellGro® HPC Cytokines

E. Zino et al. (2004)

A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood, 103: 1417-24

G. Kögler et al. (2004)

A New Human Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent Differentiation Potential. J. Exp. Med., 200(2): 123-135

Manufacturer

CellGenix GmbH
Am Flughafen 16 | 79108 Freiburg | Germany
Tel. +49 761 88889-0 | Fax +49 761 88889-830
www.cellgenix.com | info@cellgenix.com

CellGro® is a registered trademark
of CellGenix in several global markets.
In North America and a few other countries
CellGro® reagents are marketed under CellGenix™.



Reference List: CellGro® / CellGenix™ Products

CellGro® SCGM for HPC

A. Kiani et al. (2007)

Expression analysis of nuclear factor of activated T cells (NFAT) during myeloid differentiation of CD34+ cells: regulation of Fas ligand expression of megakaryocytes. *Exp. Hemat.* 35(5): 757-770

J. Szulc et al. (2006)

A versatile tool for conditional gene expression and knockdown. *Nature Methods*, 3(2): 109-116

J. Oswald et al. (2006)

Gene Expression Profile of CD34+ Hematopoietic Cells Expanded in a Collagen I Matrix. *Stem Cells*, 24(3): 494-500

CellGro® SCGM for MSC

R. Pytlik et al. (2009)

The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering. *Biomaterials* 30(20): 3415-3427

CellGro® SCGM for NK cells

O.B. Hershkovitz (2009)

NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. *J Immunol* 183:2610-21

D. Cho and D. Campana (2009)

Expansion and activation of natural killer cells for cancer immunotherapy. *Korean J Lab Med* 29:89-96

E. Alici et al. (2008)

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. *Blood*, 111(6): 3155-62

H. Guven et al. (2005)

Efficient gene transfer into primary human natural killer cells by retroviral transduction. *Exp. Hemat.*, 33(11): 1320-28

Morris R.J., Chong L.K., Wilkinson G.W., Wang E.C. (2005)

A high-efficiency system of natural killer cell cloning. *J Immunol. Meth.*, 307(1,2):24-33

Tomasec P., Wang E.C., et al. (2005)

Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. *Nature Immunol.*, 6(2):181-88

Romanski A, Bug G. et al. (2005)

Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. *Experimental Hematology*, 33(3): 344-52

Manufacturer

CellGenix GmbH
Am Flughafen 16 | 79108 Freiburg | Germany
Tel. +49 761 88889-0 | Fax +49 761 88889-830
www.cellgenix.com | info@cellgenix.com

CellGro® is a registered trademark
of CellGenix in several global markets.
In North America and a few other countries
CellGro® reagents are marketed under CellGenix™.

Reference List: CellGro® / CellGenix™ Products

T. Igarashi et al. (2004)

Enhanced cytotoxicity of allogenic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. *Blood*, 104(1): 170-77

Guven H., Gilljam M. et al. (2003)

Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. *Leukemia*, 17: 1973-80

VueLife® Culture Bags & CellGro® SCGM for NK cells

H. Fujisaki et al (2009)

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. *Cancer Res* 69:4010-7

Milani, V., S. Stangl, R. Issels, M. Gehrmann, B. Wagner, K. Hube, D. Mayr, W. Hiddemann, M. Molls, and G. Multhoff (2009)

Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report. *J Transl Med* 7:50

S. Jarnjak-Jankovic, H. Hammerstad et al. (2007)

A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines. *BMC Cancer*, 7: 119

VueLife® Culture Bags

M. de Lima et al. (2008)

Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. *Bone Marrow Transplantation*, [Epub.]: 1-8

M. Hendrikx et al. (2006)

[Clinical Trial] Recovery of Regional but Not Global Contractile Function by the Direct Intramyocardial Autologous Bone Marrow Transplantation. *Circulation*, 114: I-101-107

T.G. Berger et al. (2005)

Efficient elutriation of monocytes within a closed system (Elutra™) for clinical-scale generation of dendritic cells. *J. Immunol. Meth.*, 298(1,2): 61-72

S.W. Krause et al. (2004)

[Clinical Trial] Treatment of Colon and Lung Cancer Patients with ex Vivo Heat Shock Protein 70-Peptide-Activated, Autologous Natural Killer Cells. *Clin. Can. Res.*, 10: 3699-3707

Manufacturer

CellGenix GmbH
Am Flughafen 16 | 79108 Freiburg | Germany
Tel. +49 761 88889-0 | Fax +49 761 88889-830
www.cellgenix.com | info@cellgenix.com

CellGro® is a registered trademark of CellGenix in several global markets.
In North America and a few other countries
CellGro® reagents are marketed under CellGenix™.